Cargando…

Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival

BACKGROUND AND AIMS: Patients with liver disease acquire complex changes in their hemostatic system, which results in a fragile rebalanced status. The status of the fibrinolytic system is controversial, as is the role of fibrinolytic dysfunction in bleeding and thrombosis in patients with cirrhosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Blasi, Annabel, Patel, Vishal C., Adelmeijer, Jelle, Azarian, Sarah, Hernandez Tejero, Maria, Calvo, Andrea, Fernández, Javier, Bernal, William, Lisman, Ton
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187291/ https://www.ncbi.nlm.nih.gov/pubmed/31465557 http://dx.doi.org/10.1002/hep.30915

Ejemplares similares

Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF
por: Blasi, Annabel, et al.
Publicado: (2019)

Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates
por: Blasi, Annabel, et al.
Publicado: (2021)

Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2023)

In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2018)

Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021)

In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID‐19 patients on anticoagulation
por: Blasi, Annabel, et al.
Publicado: (2020)

The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
por: Driever, Ellen G., et al.
Publicado: (2022)

Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis
por: Meltzer, Mirjam E, et al.
Publicado: (2008)

Global hemostatic status in patients with acute‐on‐chronic liver failure and septics without underlying liver disease
por: Lisman, Ton, et al.
Publicado: (2020)

More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC
por: Zanetto, Alberto, et al.
Publicado: (2021)

Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis
por: Potze, Wilma, et al.
Publicado: (2014)

Aprotinin Inhibits Thrombin Generation by Inhibition of the Intrinsic Pathway, but is not a Direct Thrombin Inhibitor
por: Lisman, Ton, et al.
Publicado: (2021)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome
por: von Meijenfeldt, Fien A., et al.
Publicado: (2021)

Evidence against a role for platelet-derived molecules in liver regeneration after partial hepatectomy in humans
por: Kirschbaum, Marc, et al.
Publicado: (2016)

Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis
por: Riva, Antonio, et al.
Publicado: (2020)

Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease
por: von Meijenfeldt, Fien A., et al.
Publicado: (2020)

Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus
por: Driever, Ellen G., et al.
Publicado: (2021)

Bleeding and Thrombosis in Patients With Cirrhosis: What’s New?
por: Lisman, Ton
Publicado: (2023)

Determinants of hypofibrinolysis in patients with digestive tract cancer
por: Gronostaj, Katarzyna, et al.
Publicado: (2016)

Development and application of global assays of hyper‐ and hypofibrinolysis
por: Ilich, Anton, et al.
Publicado: (2019)

Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation
por: Arshad, Freeha, et al.
Publicado: (2014)

Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin
por: Burlage, Laura C., et al.
Publicado: (2019)

Diastolic Dysfunction Is a Predictor of Poor Survival in Patients with Decompensated Cirrhosis
por: Behera, Manas Kumar, et al.
Publicado: (2021)

Fibrin clot properties and thrombus composition in cirrhosis
por: Driever, Ellen G., et al.
Publicado: (2023)

Elevated Plasma Levels of Cell‐Free DNA During Liver Transplantation Are Associated With Activation of Coagulation
por: von Meijenfeldt, Fien A., et al.
Publicado: (2018)

Haemostasis patterns in patients with acute-on-chronic liver failure and acute decompensation of cirrhosis including thromboelastometric tests with and without the addition of Protac: a pilot study
por: Calvo, Andrea, et al.
Publicado: (2022)

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
por: Kearney, Katherine, et al.
Publicado: (2017)

Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19
por: Schrick, Diana, et al.
Publicado: (2021)

VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure
por: Driever, Ellen G., et al.
Publicado: (2021)

Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2018)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Elevated factor V activity and antigen levels in patients with Covid‐19 are related to disease severity and 30‐day mortality
por: von Meijenfeldt, Fien A., et al.
Publicado: (2021)

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge
por: von Meijenfeldt, Fien A., et al.
Publicado: (2021)

Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis
por: McPhail, Mark J.W., et al.
Publicado: (2016)

Improving Survival in Patients with Decompensated Cirrhosis
por: Amarapurkar, Deepak, et al.
Publicado: (2011)

Thromboelastography does not predict outcome in different etiologies of cirrhosis
por: Hugenholtz, Greg C.G., et al.
Publicado: (2017)

Efficacy of pro‐ and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery
por: Bos, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n3srp2mgrj63g8qkpqgni4ul0m